Promoted Content Promoted Content

X

Find Novel Musculoskeletal Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ARO-XDH

            Therapeutic Area: Musculoskeletal Product Name: ARO-XDH

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Horizon Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 21, 2021

            Details:

            Arrowhead will conduct all activities through preclinical stages of development of the siRNA therapeutic, ARO-XDH. Horizon will receive a worldwide exclusive license to ARO-XDH and will be wholly responsible for clinical development and commercialization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AM3101

            Therapeutic Area: Musculoskeletal Product Name: AM3101

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Photon Fund

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Financing March 25, 2021

            Details:

            The proceeds from the financing will enable Amplicore to complete the preclinical development of its two leading products, AM3101 and AM1101, and position the company for the next round of financing.